6 days ago
7
MarketBeat
Fri, March 27, 2026 astatine 9:07 AM CDT 8 min read
-
Humacyte reported aboriginal commercialized traction for Symvess with 27 VAC approvals and orders from 27 hospitals (most reordering), generating $1.4M successful full-year merchandise sales, and said a caller $17,000 terms constituent has improved VAC support rates and repetition usage.
-
The institution expects a pre-specified interim investigation of the V012 signifier III dialysis-access proceedings by aboriginal June 2026 (first 80 patients astatine 1 year) and plans to taxable a supplemental BLA successful H2 2026 combining V012 and V007 information to prosecute a dialysis indication.
-
Financially, an $8.9M inventory reserve importantly accrued outgo of goods sold and contributed to a Q4 nett nonaccomplishment of $24.8M (FY nett nonaccomplishment $40.8M), but Humacyte ended 2025 with $50.5M currency and raised ~$23M post-year-end positive entree to a recognition installation up to $77.5M (including a $40M tranche funded).
-
Interested successful Humacyte, Inc.? Here are 5 stocks we similar better.
Humacyte (NASDAQ:HUMA) outlined aboriginal commercialized traction for Symvess and provided updates crossed its pipeline during its fourth-quarter and full-year 2025 net call, portion besides detailing a twelvemonth that included archetypal merchandise revenue, a ample inventory reserve charge, and caller financing activity.
Chief Executive Officer Dr. Laura Niklason said the institution continued to execute the U.S. marketplace motorboat of Symvess and took steps to grow internationally. Humacyte reported 27 Veterans Affairs Committee (VAC) approvals for Symvess successful the U.S., with different 43 VAC committees conducting reviews. Management said its occurrence complaint with VAC submissions is astir 70%.
→ Microsoft’s Next AI Leg: Can MSFT Still Outperform From Here?
Humacyte said 27 hospitals person ordered Symvess to date, and the bulk person reordered. Fourth-quarter merchandise income were $0.4 cardinal and full-year merchandise income were $1.4 million.
On pricing, Niklason said the institution has seen a affirmative effect to a caller terms constituent of $17,000, which she said aligns with different products utilized by vascular and aortic surgeons. She linked the terms alteration to a higher VAC support complaint and accrued usage and repetition usage, portion noting that VAC timelines stay lengthy astatine astir six to 9 months, followed by contracting.
→ Is 2026 the Year of Space Stocks? 2 Stocks to Watch
To streamline contracting, Niklason said Humacyte has begun engaging with radical purchasing organizations (GPOs) and is besides moving with integrated transportation networks (IDNs). She said GPO contracts would not destruct the VAC process but could trim the request for hospital-by-hospital contracting.
English (CA) · 
English (US) · 
Spanish (MX) ·